NYSE:KVUEPersonal Products
Kenvue (KVUE) Gains FDA Backing As Valuation Questions Return
The FDA’s approval of Tylenol with Naproxen has put Kenvue (KVUE) back in the spotlight, as investors weigh what this new over the counter pain reliever might mean for the stock.
See our latest analysis for Kenvue.
The FDA approval follows a period of building momentum in Kenvue’s share price, with an 11.32% year-to-date share price return and a 9.98% 90-day share price return, even as the 1-year total shareholder return declined 11.67%.
If this kind of catalyst has caught your attention, it...